Company news

Ipsen SA news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ipsen delivers outstanding sales growth in the first nine months of 2026 and further upgrades its full-year guidance

October 21, 2026

Ipsen - September 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital

October 7, 2026

Ipsen - September 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital

October 6, 2026

IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2026

September 28, 2026

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 39 - 2026

September 27, 2026

IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2026

September 22, 2026

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 38 - 2026

September 21, 2026

Ipsen appoints Mariette Finet to its Board of Directors

September 18, 2026

Ipsen nomme Mariette Finet administratrice au sein de son Conseil d’administration

September 17, 2026

Correction: IPSEN - Buy-back programme - Art 5 of MAR - Week 36- 2026

September 15, 2026

IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2026

September 14, 2026

Ipsos: Kelly Beaver accelerates the execution of the Horizons strategic plan

September 14, 2026

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 37 - 2026

September 13, 2026

IPSEN - Buy-back programme - Art 5 of MAR - Week 36- 2025

September 7, 2026

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 36 - 2025

September 6, 2026

Ipsen - August 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital

September 3, 2026

Ipsen - Août 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

September 2, 2026

IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2026

August 31, 2026

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 35 - 2026

August 30, 2026

IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2026

August 24, 2026

Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline

August 21, 2026

IPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 2026

August 17, 2026

IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2026

August 10, 2026

IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2026

August 3, 2026

Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance

July 30, 2026

Ipsen nominates Catherine Bradley to its Board of Directors as independent Director

July 29, 2026

IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2026

July 27, 2026

Ipsen provides update on Phase III BOLD trial in biliary atresia

July 24, 2026

Ipsen - Corrective statement amending the monthly disclosure of the total number of shares and voting rights as of June 30, 2026

July 22, 2026

Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline

July 22, 2026

IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2026

July 21, 2026

IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2026

July 15, 2026

Ipsen: IQIRVO® demonstrates statistically significant improvement in ALP normalization in patients with PBC in Phase IIIb ELSPIRE study

July 13, 2026

Ipsen - Dysport is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine

July 10, 2026

Ipsen - June 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital

July 9, 2026

Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.

July 9, 2026

Ipsen - Half year statement - 2026 06 30

July 7, 2026

IPSEN - Buy-back programme - Art 5 of MAR - Week 27- 2026

July 6, 2026

IPSEN - Buy-back programme - Art 5 of MAR - Week 26- 2026

July 3, 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

July 1, 2026

Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline

June 29, 2026

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2026

June 22, 2026

IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2026

June 15, 2026

Ipsen welcomes the European Union’s publication of the Joint Clinical Assessment for Ojemda® (tovorafenib)

June 9, 2026

Ipsen - May 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital

June 8, 2026

IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2026

June 8, 2026

IPSEN - Buy-back programme - Art 5 of MAR - Week 22 - 2026

June 1, 2026

Ipsen announces the launch of an Employee Shareholding Plan

May 29, 2026

IPSEN - Buy-back programme - Art 5 of MAR - Week 21 - 2026

May 27, 2026

National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare

May 20, 2026

Older news releases →

Calls

The 5 newest of 7 calls. Every call is listed under its year.

Decks

The 5 newest of 88 decks. Every deck is listed under its year.